Evidence map›Paper›PMID 35907971›Full record

ReviewClinical rheumatology2022

Health disparities in systemic lupus erythematosus-a narrative review.

Bilal Hasan, Alice Fike, Sarfaraz Hasni

Open access · bronzeAbstract readReview
In one paragraph

Review in Clinical rheumatology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
43citing papers in PubMed, 2 pooled it
8.5field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

43 citing papers in PubMed, 2 syntheses or guidelines pooled it, 56 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Clinical and Demographic Predictors of Optic Neuritis Subtype.Neuro-ophthalmology (Aeolus Press) · 2026
    Article
  14. Observational
  15. Observational
  16. Review
  17. How to Make AI Ready for Rheumatology: Challenges and Perspectives.Mediterranean journal of rheumatology · 2025
    Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Bilal HasanNational Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH, Bethesda, MD, USA. bilal.hasan@nih.gov.ORCID http://orcid.org/0000-0003-1423-6914
Alice FikeNational Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH, Bethesda, MD, USA.ORCID http://orcid.org/0000-0003-2597-1981
Sarfaraz HasniNational Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH, Bethesda, MD, USA.ORCID http://orcid.org/0000-0002-4164-8837
National Institute of Arthritis and Musculoskeletal and Skin Diseases · US

Funding

Lupus Clinical TrialsZIAAR041232 · NIAMS · NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES · PI HASNI, SARFARAZ · 2022 to 2025
$12.9M
Studies of the Natural History of Rheumatic DiseasesZIAAR041170 · NIAMS · NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES · PI HASNI, SARFARAZ · 2009 to 2025
$11.1M
6 · The paper itself

Abstract

purpose of reviewTo describe root causes of health disparities by reviewing studies on incidence and outcomes of systemic lupus erythematosus (SLE) related to ethnic, race, gender, or socioeconomic differences and to propose solutions. RECENT

findingsSLE outcomes have steadily improved over the past 40 years but are not uniformly distributed across various racial and ethnic groups. Belonging to racial and ethnic minority has been cited as a risk factor for more severe disease and poor outcome in SLE. Population-based registries have demonstrated that Black patients with SLE have significantly lower life expectancy compared to White patients. Lower socioeconomic status has been shown to be one of the strongest predictors of progression to end stage renal disease in lupus nephritis. An association between patient experiences of racial discrimination, increased SLE activity, and damage has also been described. The lack of representation of marginalized communities in lupus clinical trials further perpetuates these disparities. To that end, the goal of a rheumatology workforce that resembles the patients it treats has emerged as one of many solutions to current shortfalls in care. Disparities in SLE incidence, treatment, and outcomes have now been well established. The root causes of these disparities are multifactorial including genetic, epigenetic, and socioeconomic. The underrepresentation of marginalized communities in lupus clinical trials further worsen these disparities. Efforts have been made recently to address disparities in a more comprehensive manner, but systemic causes of disparities must be acknowledged and political will is required for a sustained positive change.

Indexed as

Lupus Erythematosus, SystemicLupus NephritisEthnicityHumansIncidenceMinority GroupsClinical trialsDisparitiesEpidemiologySLE

Identifiers

PMID35907971
PMCPMC9340727
OpenAlexW4288902265

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.